Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NAAA | Q02083 | 1/20 | 0.81 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | STAT1 | P42224 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | ME2 | P23368 | 1/20 | 0.63 |
| ▸ | ME1 | P48163 | 1/20 | 0.63 |
| ▸ | ME3 | Q16798 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087869 | 0.98 | NPC1 (0.96) | NPC1TDP1NAAAFKBP1APOLB | |
| SCHEMBL6285963 | 0.98 | NPC1 (0.96) | NPC1TDP1NAAAFKBP1APOLB | |
| SCHEMBL25432319 | 0.96 | NPC1 (0.93) | NPC1TDP1NAAAFKBP1APOLB | |
| SCHEMBL7131839 | 0.92 | NPC1 (0.86) | NPC1TDP1NAAAFKBP1APOLB | |
| SCHEMBL16333764 | 0.90 | NAAA (1.00) | NPC1TDP1NAAAFKBP1APOLB | |
| SCHEMBL8599293 | 0.89 | NPC1 (0.81) | NPC1TDP1NAAAHPGDSMN1; SMN2 | |
| SCHEMBL10371234 | 0.88 | NPC1 (0.78) | NPC1TDP1NAAAHPGDSMN1; SMN2 | |
| SCHEMBL7376148 | 0.86 | NPC1 (0.76) | NPC1TDP1NAAAHPGDSMN1; SMN2 | |
| SCHEMBL3796874 | 0.86 | NPC1 (0.75) | NPC1TDP1NAAAFKBP1APOLB | |
| SCHEMBL14747850 | 0.84 | NPC1 (0.73) | NPC1TDP1NAAAFKBP1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183281-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-27 | — | — | US | claimed |
| US-7074783-B2 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | claimed |
| EP-1501807-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | claimed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-112898233-B | Method for preparing amide compound by photocatalytic nitrogen-containing heterocyclic compound | 中南大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-112898233-A | Method for preparing amide compound by photocatalytic nitrogen-containing heterocyclic compound | 中南大学 | 2021-06-04 | — | — | CN | disclosed |
| CN-108341733-B | Novel electronic salt system and reduction method of unsaturated hydrocarbon compound | 中国农业大学 | 2021-01-08 | — | — | CN | disclosed |
| EP-2200609-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2010-06-30 | — | — | EP | disclosed |
| EP-2198864-A1 | Pharmaceutical compositions having an analgesic effect and containing 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds | Allergan, Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| US-7635775-B2 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-7074783-B2 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1633349-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004098590-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293332-A1 | Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | NPC1 3747/4885TDP1 4459/4885NAAA 275/4885 |
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | NPC1 1217/4885TDP1 3017/4885NAAA 1257/4885 |
| US-20040147520-A1 | Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists | BDKRB2, BDKRB1, PDXK | NPC1 3767/4885TDP1 4513/4885NAAA 64/4885 |
| US-20040138208-A1 | Sulfonylbenzodiazepinone acetamides as bradykinin antagonists | BDKRB1, BDKRB2, HRH2 | NPC1 2115/4885TDP1 3995/4885NAAA 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.